Rashmi S. Goswami^1,3, Mahadeo A. Sukhai^1,2, Mariam Thomas^1,2, Patricia P. Reis¹ and Suzanne Kamel-Reid<sup>1,2,3

1</sup>Division of Applied Molecular Oncology, Princess Margaret Hospital/the Ontario Cancer Institute, University Health Network, Toronto, ON, Canada. ²Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. ³Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Abstract

Microarray technology is a powerful tool, which has been applied to further the understanding of gene expression changes in disease. Array technology has been applied to the diagnosis and prognosis of Acute Myelogenous Leukemia (AML). Arrays have also been used extensively in elucidating the mechanism of and predicting therapeutic response in AML, as well as to further define the mechanism of AML pathogenesis. In this review, we discuss the major paradigms of gene expression array analysis, and provide insights into the use of software tools to annotate the array dataset and elucidate deregulated pathways and gene interaction networks. We present the application of gene expression array technology to questions in acute myelogenous leukemia; specifically, disease diagnosis, treatment and prognosis, and disease pathogenesis. Finally, we discuss several new and emerging array technologies, and how they can be further utilized to improve our understanding of AML.

Discussion
No comments yet...Be the first to comment.

 CONNOTEA  CITEULIKE FACEBOOK LINKED IN